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 3 
Abstract 4 
Aims 5 
To develop a list of hospital based paediatric prescribing indicators that can be used to 6 
assess the impact of electronic prescribing or clinical decision support tools on paediatric 7 
prescribing errors. 8 
Methods 9 
Two rounds of an electronic consensus method (eDelphi) were carried out with 21 expert 10 
panellists from the UK.  Panellists were asked to score each prescribing indicator for its 11 
likelihood of occurrence and severity of outcome should the error occur.  The scores were 12 
combined to produce a risk score and a median score for each indicator calculated.  The 13 
degree of consensus between panellists was defined as the proportion that gave a risk score 14 
in the same category as the median.  Indicators were included if a consensus of 80% or 15 
higher was achieved and were in the high risk categories. 16 
Results 17 
Each of the 21 panellists completed an exploratory round and two rounds of scoring.  This 18 
identified 41 paediatric prescribing indicators with a high risk rating and greater than 80% 19 
consensus.  The most common error type within the indicators was wrong dose (n= 19) and 20 
the most common drug classes were antimicrobials (n=10) and cardiovascular (n = 7). 21 
Conclusions 22 
A set of 41 paediatric prescribing indicators describing potential harm for the hospital setting 23 
have been identified by an expert panel.  The indicators provide a standardised method of 24 
evaluation of prescribing data on both paper and electronic systems.  They can also be used 25 
to assess implementation of clinical decision support systems or other quality improvement 26 
initiatives. 27 
What is already known about this subject 28 
 Prescribing errors are common in the paediatric setting 29 
 Prescribing indicators can be used to measure or monitor the accuracy of prescribing 30 
 There are no validated paediatric prescribing indicators for the hospital setting 31 
What this study adds 32 
 A set of 41 prescribing indicators specific for the UK hospital paediatric setting 33 
 A standardised method for assessing the impact of electronic prescribing on high risk 34 
medicines 35 
 36 
Introduction 37 
The use of medication to treat disease, alleviate symptoms and prevent illness is the most 38 
common intervention used in healthcare.   The vast majority of medication does not cause 39 
harm.  However, all medicines carry some level of risk.  Medication errors are common in 40 
hospital practice1 and evidence suggests possibly more common in children.2  Determining 41 
the harm caused by these errors is vital to be able to understand how interventions might be 42 
targeted to reduce the risk of harm.  Methods for determining harm vary considerably.  Some 43 
studies use a severity scale for determining harm, scored by the researcher or by obtaining 44 
consensus between a number of healthcare professionals.3, 4   45 
The same methodologies for identifying prescribing errors and harm in adult patients have 46 
been used in the paediatric setting.  Prescription review often by hospital pharmacists yields 47 
large numbers of potential prescribing errors often with low or no harm.4, 5 This make is 48 
difficult to determine the impact of any change or improvement. 49 
Trigger tools look for indicators of harm rather than specific errors, for example a high 50 
International Normalised Ratio (INR) indicates that a potential error with warfarin may have 51 
occurred and requires checking to confirm this. Triggers for the paediatric setting have been 52 
described in the literature.  Stockwell et al  recently published a paediatric harm 53 
measurement tool contained 51 triggers, including 21 medication related triggers.6   Trigger 54 
tools such as this provide a standard method of identifying errors but  they require extensive 55 
retrospective case note review in order to identify firstly the trigger and then any subsequent 56 
medication related harm.  57 
Prescribing indicators are a valid standardised way of measuring or monitoring an area of 58 
prescribing where changes in prescribing or putative improvement require evaluation either 59 
prospectively or retrospectively.  Adult prescribing indicators have been developed in several 60 
settings in the UK.7-10  Thomas et al11 published a set of adult prescribing indicators for the 61 
hospital setting.  Using an eDelphi methodology, consensus on a set of 81 indicators was 62 
achieved.  They describe prescribing errors which have the risk of causing significant harm. 63 
The aim of this research was to create a set of paediatric prescribing indicators for the 64 
hospital setting that can be used to assess the impact of electronic prescribing. 65 
Method 66 
 While evidence-based medicine is the gold standard approach to care, there, remain vast 67 
swathes of medicine where evidence is lacking or incomplete.  This is often due to the rare 68 
nature of a condition and the subsequent difficulty in running a randomised controlled trial.  69 
The Delphi method is based on the idea that an accurate and reliable consensus can be 70 
gained by consulting a panel of experts and accepting the group consensus.  Its use in 71 
health services research includes guideline development,12 outcome measures for primary 72 
health care research13, drug related mortality,14 high acuity paediatric conditions15 and the 73 
design of a paediatric pharmaceutical care model.16  Importantly the method has been used 74 
extensively to develop prescribing indicators for general practice,8, 9, 17-20 and hospital adult 75 
in-patients.11  Based on the validated use thus far, the Delphi technique was selected to gain 76 
consensus opinion on paediatric prescribing indicators, from a range of both paediatric 77 
physicians and pharmacists. 78 
 79 
Expert Panel Selection 80 
A list of potential panellists was generated by the research team from networks via the Royal 81 
College of Paediatrics and Child Health (RCPCH) and the Neonatal and Paediatric 82 
Pharmacists Group (NPPG).  Additional contacts were made through research links with a 83 
National Institute of Healthcare Research (NIHR) programme grant investigating the impact 84 
of electronic prescribing.  An email invitation was sent to 39 potential panellists requesting 85 
their participation, along with a summary of the proposed research.  Panellists were general 86 
paediatricians, paediatric pharmacists and paediatric clinical pharmacologists from across 87 
the UK.  Panellist information was collected on the total number of years of paediatric 88 
experience, and experience with electronic prescribing systems.  Out of the 39 people 89 
invited, 24 agreed to participate.  This achieved the target number of at least 20 panel 90 
members, comparable to the number used in a similar Delphi study.11 91 
Identifying Potential Indicators 92 
Information was gathered from a variety of sources (Table 1) on paediatric prescribing errors 93 
by the lead researcher and assessed for their suitability according to the inclusion and 94 
exclusion criteria, by the research team.   95 
 96 
 97 
Inclusion 98 
 The indicator describes a prescribing error relating to a specific drug 99 
 The indicator is specific to the hospital paediatric setting 100 
Exclusion 101 
 The indicator describes a prescribing practice not routinely undertaken in paediatric 102 
hospital settings 103 
 The indicator describes an error that would not be amenable to clinical decision 104 
support or electronic prescribing 105 
 Extraction of data for the indicator from hospital records is not likely to be feasible 106 
 The indicator describes a failure to monitor 107 
 The indicator describes errors relating to the administration or dispensing of a drug 108 
 109 
The eDelphi Process 110 
Exploratory Round 111 
The 24 panellists were sent the initial list of indicators for the exploratory round.  They were 112 
instructed to review each indicator for relevance and possible modification to ensure clarity.  113 
They also had the opportunity at this stage to suggest additional indicators that had not been 114 
identified by the research team.  The additional indicators were collated and reviewed and, if 115 
appropriate, included in the final indicator list used for round one of the eDelphi process.  116 
Panellists were also made aware of the reasons for exclusion of any suggested indicators.   117 
Round One 118 
In round one panellists were asked to rate each indicator for its likelihood of occurrence and 119 
severity of harm should it occur.  The scoring system used was based on the National 120 
Patient Safety Agency scale in common use in UK hospitals REF (Table 1) and allowed 121 
identification of indicators with the greatest clinical risk.  The panellist scores were converted 122 
into a risk score using the matrix.  The median risk scores for each indicator were then 123 
calculated, allowing the indicators to be divided into groups based on their risk scores.   124 
Round Two 125 
In round two, each panellist was sent the indicators, the median likelihood and severity 126 
scores from the panel and the individual panellist’s original scores from round 1.  Panellists 127 
were then asked to review their scores in light of the median scores and were given the 128 
opportunity to either maintain their original judgement or modify their scores in line with the 129 
majority of the group.  The median scores were then re-calculated for each indicator and the 130 
level of consensus determined.  Indicators with a median risk score greater than 8 (high or 131 
extreme) and at least 80% consensus were then considered to have achieved an adequate 132 
level of consensus and therefore inclusion into the final list. 133 
Results 134 
Prior to the exploratory round, a total of 179 potential indicators were identified from the 135 
resources listed above (Table 1).  The research team reviewed each indicator against the 136 
inclusion and exclusion criteria resulting in a final list of 100 indicators; 77 indicators were 137 
identified from a single source, 23 from two or more sources. 138 
The exploratory stage and rounds one and two were completed by 21 of the 24 panellists 139 
who had originally agreed to take part.  Table 3 summarises the panellists’ levels of 140 
experience, profession and location type.  The panel comprised of 8 pharmacists with a total 141 
of 181 years of paediatric experience, and 13 paediatricians with a total of 256 years 142 
experience.  Panellists had a total of  91 years of experience with electronic prescribing. 143 
During the exploratory round, 75 new indicators were proposed by the panel and reviewed 144 
by the research team, 34 of which were included in round one.  In addition, nine of the 145 
original indicators were removed and one reworded following the comments and suggestions 146 
of the panel.  Typical reasons for exclusion were that the indicator described a cause of an 147 
error rather than an error itself, that the indicator was non-specific and would relate to 148 
numerous drugs or that the issue would be captured by another indicator. This resulted in a 149 
final list of 125 indicators for round one. 150 
Following two rounds of scoring, 41 of the indicators were considered high risk by 151 
consensus; these are summarised in table 4.  None of the indicators were assessed as 152 
extreme risk by the panellists.   153 
The 41 indicators include 34 different drugs or classes from the following therapeutic groups; 154 
gastrointestinal (n=1), cardiovascular (n=7), respiratory (n=1), central nervous system (n=3), 155 
antimicrobials (n=10), endocrine (n=2), immunosuppression (n=6), fluids and electrolytes 156 
(n=1), musculoskeletal (n=2) and anaesthesia (n=1).  157 
The most frequent error type identified as high risk was dosing (n= 19) with drug-drug 158 
interactions (n=7) and clinical contraindications (n=6) the next two most frequent error types. 159 
Discussion 160 
The eDelphi process has identified 41 high risk prescribing indicators for the paediatric 161 
hospital setting.  They can potentially be used to monitor the impact of electronic prescribing 162 
or clinical decision support tools.  To the authors’ knowledge, this is the first set of 163 
prescribing indicators for paediatric patients in the hospital setting.  However, other work has 164 
attempted to identify high risk medicines in this setting.   165 
The consensus process used to derive the indicators involved a panel consisting of 21 166 
paediatricians and paediatric pharmacists all of whom complete two rounds of scoring, 167 
limiting any bias introduced by missing responses.  168 
Nearly half (n = 19) of the final 41 indicators related to dosing errors.  This is not surprising 169 
since dose errors account for the majority of the indicators identified for rounds 1 and 2.  170 
This is likely influenced by the fact that dosing errors are the most common error type 171 
reported in paediatrics.21-23  Drugs with known risks such as gentamicin, phenytoin and 172 
methotrexate were included in the dosage indicators; however, “lower risk” drugs such as 173 
meropenem, ceftriaxone and domperidone are also present.  This may reflect, in the case of 174 
the antimicrobials, the relatively serious clinical indications in which these drugs are used 175 
and the need to prescribe the correct dose to avoid treatment failure as well as heightened 176 
awareness as a result of antimicrobial stewardship.  Or; in the case of domperidone the 177 
relatively recent publicity relating to adverse reactions.24   178 
Previously published work has identified high-alert medicines within paediatrics.  Maaskant 179 
et al25 published a list containing fourteen specific drugs and 4 medication classes of high-180 
alert medications. Comparing this with our prescribing indicators shows that 10 of the 181 
individual drugs and three of the drug classes are duplicated.  The four high-alert drugs not 182 
identified in our prescribing indicators are all infusions commonly used in intensive care 183 
areas, such as dopamine and noradrenaline.  Reference to errors involving infusions was 184 
excluded from our research because the reported incidents all related to errors occurring as 185 
a result of incorrect administration or infusion preparation rather prescribing.    186 
The high-alert drug class from Masskant et al’s25 report that is not included in our prescribing 187 
indicators relates to parenteral nutrition. Errors reported relating to parenteral nutrition 188 
concern administration or preparation errors rather than prescribing.  This possibly reflects 189 
UK practice in terms of these medications where standard prescriptions and electronic 190 
systems for parenteral nutrition have been developed to prevent errors at the prescribing 191 
stage.   192 
Stockwell et al6 published a list of paediatric triggers developed using an eDelphi technique 193 
and an international panel.  From their list of 21 triggers relating to medicines, 11 also 194 
appear in our paediatric prescribing indicator list.  The triggers describe adverse events that 195 
could result from any incorrect use of a medicine.  For example the administration of 196 
Digibind® could be triggered by an error in the prescribing, dispensing, administration or 197 
monitoring of digoxin.  This is an appropriate way of identifying an adverse event after it has 198 
occurred.  Our indicators, however, are specific for the prescribing process and can be used 199 
to identify errors at the prescribing stage, which may be in advance of the medicine being 200 
administered.  This can tell us whether quality improvement interventions such as 201 
ePrescribing can prevent the ‘potential’ for harm occurring. 202 
Many of the paediatric indicators for the exploratory round were derived from the adult 203 
indicators previously published.11  The final list of 41 paediatric indicators contain 28 204 
indicators modified from the research conducted in adult medicine.  Many of the remaining 205 
indicators were related to specific paediatric settings or medicines not usually classed as 206 
high risk in adults as such as meropenem, as discussed above.   207 
Reports of the incidence of prescribing errors in the paediatric setting vary between 7 and 208 
13%.22, 26 This is partly because there is no standard definition of what and how to collect 209 
information about errors.  Studies use different data collection methods and different 210 
definitions of medication error.27  This lack of standardisation makes comparison between 211 
reports difficult to assess. 212 
Prescribing indicators can be used to assess the impact of a safety improvement 213 
intervention by standardising both pre- and post-implementation data collection.  The 214 
objective nature of these data would allow comparisons and conclusions to be drawn and 215 
provide more robust evidence across healthcare settings.  The standardisation means that 216 
for the first time, comparisons can be made between hospitals and different initiatives. 217 
The indicators can also be used to optimise the capability of electronic prescribing systems, 218 
such as with the provision of complex clinical decision support to highlight and avert such 219 
errors at the point of prescribing. This also has the potential to focus alerts on high risk 220 
areas, with the advantage of reducing alert fatigue.28 221 
While the paediatric indicators described here are focused on the secondary care setting, 222 
many could be applicable to general practice.  There are currently no primary care related 223 
exclusive paediatric trigger tools published in the literature 224 
Limitations 225 
The initial list of indicators was derived from an extensive literature search and therefore, 226 
unpublished cases of medication errors would not have been included.  However, we aimed 227 
to minimise this effect by including the exploratory round so panellists had the opportunity to 228 
propose indicators they see in practice. 229 
The work is entirely UK based and as such may not have applicability in other global 230 
settings.  Lastly, as new evidence emerges and new drugs begin to be used, other potential 231 
indicators may become relevant.  The adult indicators previously cited are currently under 232 
review and if the paediatric indicators described here become extensively utilised a program 233 
of periodic review will be necessary. 234 
Conclusions 235 
Paediatric prescribing errors with the potential to cause harm have been identified by an 236 
expert panel.  The indicators provide an objective tool that can be used to collect routine 237 
prescribing data in both electronic or paper-based environments. Standardisation of what is 238 
collected will allow a better understanding of what errors are occurring in paediatrics.  239 
Without this knowledge, it is difficult to target quality improvement projects, and also inform 240 
under- and postgraduate education of paediatric prescribing. 241 
They could also be used to refine alerting systems used in electronic prescribing to target 242 
warnings and alleviate alert fatigue. 243 
The use of these paediatric indicators in combination with previously described adult 244 
indicators for the hospital setting provides a comprehensive tool that can be used to evaluate 245 
changes across a wider age range. 246 
 247 
 248 
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  327 
Table 1  328 
Table 1 - Sources used to identify indicators 
Adult indicators previously published11 
Literature Search 
National Reporting and Learning (NRLS) data29  
Local pharmacy intervention data 
Trust incident forms 
National Patient Safety Alerts 
Table 2  329 
Table 2: Scoring likelihood and severity of the errors occurring (from the UK National Patient Safety 330 
Agency Risk Matrix) 30 331 
 Likelihood 
Consequence 1  Rare 
This will probably 
never occur 
2 Unlikely 
Do not expect it to 
occur but it is 
possible it may do 
3 Possible 
This might 
occasionally occur 
4 Likely 
This will probably 
occur 
5 Almost certain 
This will 
undoubtedly occur, 
possibly frequently 
5 Catastrophic 
Leads to death, multiple 
permanent injuries, or 
irreversible health effects 
5 10 15 20 25 
4 Major 
Major injury leading to long-
term incapacity/ disability 
4 8 12 16 20 
3 Moderate 
Moderate injury requiring 
intervention 
3 6 9 12 15 
2 Minor 
Minor injury or illness 
requiring minor intervention 
2 4 6 8 10 
1 Insignificant 
No risk of patient injury or 
harm and no 
intervention required 
1 2 3 4 5 
 332 
 333 
1-3 
Low risk 
4-6 
Moderate risk 
8-12 
High risk 
15-25 
Extreme risk 
 334 
 335 
Table 3 – Experience and type of hospital for expert panel members.   336 
Position Years of 
Experience 
Years of 
Electronic 
Prescribing 
experience 
Type of Hospital 
Senior Paediatric Pharmacist 35 2 General Teaching 
Clinical Pharmacy Manager 25 3 Specialist Children’s 
Neonatal Pharmacist 32 0 General  
Consultant Pharmacist 26 21 General Teaching 
Medication Safety Pharmacist 20 11 General Teaching 
Clinical Pharmacist 12 5 Specialist Children’s  
Associate Professor of Child Health 18 1 Specialist Children’s 
Consultant Paediatrician 19 1 Specialist Children’s 
Consultant Paediatrician 24 1 Specialist Children’s 
Consultant Neonatologist 19 0 Specialist Children’s 
Specialist Registrar 10 0 Specialist Children’s 
Consultant Paediatrician 30 0 General Teaching 
Senior Lecturer Paediatric 
Pharmacology 
20 0 Specialist Children’s 
Consultant Paediatrician 20 14 General Teaching 
Lead Informatics Pharmacist 22 15 General Teaching 
Paediatric Pharmacist 9 3 Specialist Children’s 
Consultant Neonatologist 20 0 General 
Consultant Paediatrician 19 10 General 
Consultant Paediatrician 17 4 General 
Consultant Paediatrician 19 0 General 
Consultant Paediatrician 14 0 General 
 337 
 338 
Table 4 – Final list of indicators high risk with >80% consensus. 339 
Indicator Possible Outcome 
Therapeutic Class 
Error Type 
Level of 
Consensus 
Domperidone prescribed at > 
1.2mg/kg/day max 20mg 
(prolongation of QT interval, 
sudden cardiac death) 
Increased risk of arrhythmias 
and sudden cardiac death 
Gastrointestinal 
Dosing 86% 
Digoxin dose not reviewed in light 
of reduced renal function 
Risk of supratherapeutic doses 
increasing risk of adverse 
effects 
Cardiovascular 
Dosing 95% 
Potassium-sparing diuretic 
(excluding aldosterone 
antagonists) prescribed to a 
patient also receiving an ACE 
inhibitor or angiotensin-II 
receptor antagonist (Increased 
risk of severe hyperkalaemia) 
Increased risk of severe 
hyperkalaemia 
Cardiovascular 
Drug-Drug 
Interaction 
90% 
Amiodarone prescribed to a 
patient on digoxin without review 
of the digoxin dose 
Risk of digoxin toxicity 
Cardiovascular Drug-Drug 
interaction 
81% 
Beta-adrenoceptor blocking drug 
prescribed to a patient with 
asthma (Increased risk of 
bronchospasm and acute 
deterioration) 
Beta-adrenoceptor blocking 
drugs are known to cause 
bronchoconstriction in 
asthmatics, and can cause 
acute deterioration 
Cardiovascular 
Clinical 
Contraindication 
81% 
Low molecular weight heparin 
prescribed to a patient with renal 
impairment without dose 
adjustment (Increased risk of 
bleeding) 
Increased risk of bleeding with 
the dose of low molecular 
weight heparin is not adjusted 
for renal function 
Cardiovascular 
Dosing 86% 
Antiplatelet  prescribed to a 
patient with a concurrent 
bleeding disorder (Increased risk 
of bleeding) 
High risk of bleeding when 
antiplatelets prescribed to 
patients with a past medical 
history of bleeding disorders 
Cardiovascular 
Clinical 
Contraindication 
81% 
Prescribing of intravenous heparin 
infusion for treatment of 
thromboembolic event using the 
wrong dose or infusion rate based 
on local protocol (risk of toxicity 
or therapeutic failure) 
Risk of supratherapeutic or 
subtherapeutic dose of heparin 
Cardiovascular 
Dosing 86% 
Two concomitant opiate 
analgesics that are not in line with 
the WHO pain ladder (Injudicious 
use of two opiates risk of toxicity) 
Increased risk of opioid toxicity 
Central Nervous 
System 
Therapeutic 
Duplication 
86% 
Prescribing of incorrect or 
inequivalent morphine (opiate) 
dose via multiple routes. (Risk of 
toxicity) 
Oral and intramuscular doses 
are not equivalent, risk of 
therapeutic failure or toxicity 
Central Nervous 
System 
Therapeutic 
Duplication 
81% 
Phenytoin dose not reviewed in 
light of low albumin (potential for 
toxicity) 
Increased risk of phenytoin 
toxicity 
Central Nervous 
System 
Dosing 86% 
Penicillin containing compound 
prescribed to a penicillin allergic 
patient without reasoning (e.g. a 
non-allergy such as diarrhoea or 
vomiting entered as an allergy 
where the indication for penicillin 
is compelling) (Risk of 
hypersensitivity reactions) 
Contraindicated in pts with 
history of penicillin allergy. Risk 
of hypersensitivity reaction 
Anti-Microbial 
Allergy 81% 
Nitrofurantoin prescribed to a 
patient with renal impairment, 
avoid if eGFR 
<60ml/minute/1.73m2 (Risk of 
peripheral neuropathy and 
inadequate concentration in urine) 
Risk of peripheral neuropathy 
and reduced therapeutic effect 
Anti-Microbial 
Dosing 80% 
Gentamicin prescribed to a 
patient with  at least mild renal 
impairment without dose 
frequency adjustment (Increased 
risk of toxicity) 
Increased risk of toxicity 
Anti-Microbial 
Dosing 81% 
Gentamicin dose calculated based 
on actual body weight rather than 
ideal body weight in an obese 
patient (Risk of excessive dosing 
and toxicity) 
Risk of excessive dosing and 
toxicity 
Anti-Microbial 
Dosing 100% 
Macrolide antibacterial prescribed 
concomitantly with warfarin 
without appropriate dose 
adjustment or increased INR 
monitoring (Increased risk of 
bleeding) 
Macrolide antibacterials can 
reduce the metabolism of 
warfarin, causing an increase in 
the INR and an increased risk of 
bleeding 
Anti-Microbial 
Drug-Drug 
Interaction 
90% 
Co-prescribing of macrolides with 
interacting drug (QT prolongation) 
Risk of prolongation of QT 
interval and ventricular 
arrhythmia 
Anti-Microbial Drug-Drug 
Interaction 
86% 
Co-prescribing of a macrolide with 
ciclosporin or tacrolimus 
(increases plasma levels of anti-
rejection agent) 
Increased plasma concentration 
of ciclosporin 
Anti-Microbial 
Drug-Drug 
Interaction 
86% 
Vancomycin prescribed 
intravenously over less than 60 
minutes (Rapid infusion of 
vancomycin can cause severe 
reactions) 
Increased risk of infusion 
reactions 
Anti-Microbial 
Intravenous 
Rate 
81% 
Amphotericin B prescribed 
without additionally stating both 
brand name and the dose in 
mg/kg (Risk of fatal overdose due 
to confusion between lipid based 
and non-lipid  
Specification of brand name to 
reduce risk of wrong 
formulation being administered 
and resulting toxicity 
Anti-Microbial 
Drug Name 90% 
Soluble insulin prescribed to a 
patient on a when required basis 
(Increased risk of serious episodes 
of hypoglycaemia and nocturnal 
hypoglycaemia post dose) 
Increased risk of serious 
episodes of hypoglycaemia and 
nocturnal hypoglycaemia 
especially if given more than 1 
stat dose. Not managing the 
long-term condition 
Endocrine 
Clinical 
Contraindication 
85% 
Methotrexate prescribed to a 
patient with a clinically significant 
drop in white cell count or platelet 
count (Risk of bone marrow 
suppression) 
Risk of bone marrow 
suppression 
Immunosuppressant 
 
Clinical 
Contraindication 
90% 
Oral methotrexate prescribed to a 
patient with an inappropriate 
frequency (Increased risk of 
toxicity) 
Oral methotrexate should be 
dosed ONCE WEEKLY, and the 
prescription clear as to which 
day of the week this should be 
Immunosuppressant 
Dosing 100% 
Methotrexate prescribed to a 
patient with abnormal liver 
function tests (Risk of liver 
toxicity) 
Risk of liver toxicity 
Immunosuppressant 
Clinical 
Contraindication 
85% 
Methotrexate prescribed 
concomitantly with trimethoprim 
(Increased risk of haematological 
toxicity) 
Trimethoprim suppresses 
activity of dihydrofolate 
reductase - potential for 
additive effect to produce 
folate deficiency. Increased risk 
of haematological toxicity when 
methotrexate given with 
trimethoprim (including 
trimethoprim containing 
compound - co-trimoxazole) 
Immunosuppressant 
Drug-drug 
interaction 
85% 
Allopurinol prescribed 
concomitantly with 
mercaptopurine (Allopurinol 
enhances effect of 
mercaptopurine and increases risk 
of toxicity) 
Increased risk of toxicity and 
enhanced effects of 
mercaptopurine when given 
concomitantly.  The dose of 
mercaptopurine should be one 
quarter of usual dose 
Immunosuppressant 
Drug-drug 
interaction 
80% 
Potassium chloride supplements 
continued for longer than is 
required  (based on age 
appropriate local reference ranges 
approx 3.5–5.3 mmol/litre) 
(Increased risk of hyperkalaemia) 
Failure to act on potassium 
chloride monitoring and 
continuing treatment for longer 
than required risks 
hyperkalaemia 
Nutrition 
Duration 81% 
Potassium chloride infusions 
exceeding 40 mmol/litre 
prescribed to administered via the 
Intravenous administration of 
potassium chloride solutions 
exceeding 40mmol/litre should 
Nutrition 
Route 86% 
peripheral route (Peripheral 
administration risks venous 
pooling, which can lead to sudden 
high concentrations of potassium 
chloride being delivered to the 
heart provoking an arrhythmia)  
be prescribed via the central 
route to avoid arrhythmias 
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